Teriparatide Acetate
Title: Teriparatide Acetate
CAS Registry Number: 99294-94-7
Additional Names: hPTH 1-34 acetate
Manufacturers' Codes: MN-10T
Trademarks: Parathar (Rorer); Forteo (Lilly)
Line Formula: C181H292N55O51S2.yC2H4O2.xH2O
Literature References: Synthetic, biologically active polypeptide consisting of the 1-34 amino-terminal fragment of human parathyroid hormone (hPTH), q.v. Amino acid sequence: H. B. Brewer et al., Proc. Natl. Acad. Sci. USA 69, 3585 (1972). Prepn: R. H. Andreatta et al., Helv. Chim. Acta 56, 470 (1973). Revised structure: H. D. Niall et al., Proc. Natl. Acad. Sci. USA 71, 384 (1974). Prepn: R. L. Colescott, DE 2649727; idem, DE 2649848; G. W. Tregear, US 4086196 (1977, 1977, 1978 all to Armour Pharm.). Solid phase synthesis and biological activity: G. W. Tregear et al., Z. Physiol. Chem. 355, 415 (1974). Solution synthesis and biological activity: M. Takai et al., Pept. Chem. 17, 187 (1980). Clinical pharmacology: R. M. Neer et al., J. Clin. Endocrinol. Metab. 38, 420 (1977). RIA determn in plasma: J. M. Zanelli et al., J. Immunoassay 1, 289 (1980). Clinical pharmacokinetics: G. N. Kent et al., Clin. Sci. 68, 171 (1985). Clinical evaluation in osteoporosis: J. Reeve et al., Br. Med. J. 280, 1340 (1980); D. M. Slovik et al., J. Clin. Invest. 68, 1261 (1981). Diagnostic use: T. Igarashi et al., Pharmatherapeutica 3, 79 (1982); L. E. Mallette et al., J. Clin. Endocrinol. Metab. 67, 964 (1988). Review of diagnostic use in modified Ellsworth-Howard test: L. E. Mallette, Ann. Intern. Med. 109, 800-804 (1988); of pharmacology and clinical efficacy: H. Dobnig, Expert Opin. Pharmacother. 5, 1153-1162 (2004).
Therap-Cat: Treatment of osteoporosis. Diagnostic aid (hypocalcemia).
Keywords: Antiosteoporotic; Calcium Regulator; Diagnostic Aid.

Others monographs:
Meconic AcidHexadimethrine BromidePamicogrelTerazosin
α-TerthienylSultroponiumTsuduranineCalcium Permanganate
PregnanediolDiphenylketeneFerrous OxalateDiphenylamine-2,2'-dicarboxylic Acid
Propylidene ChlorideRosuvastatinAnthrimidePolidexide
©2016 DrugLead US FDA&EMEA